ArticleReimer RR.
Surg Clin North Am. 1978 Aug;58(4):843-9.
Several chemotherapeutic agents given singly or in combination are capable of producing significant tumor regression in recurrent breast cancer. Such remissions improve both the quality and duration of life. To date, the most active combinations have been variations of Cooper's CMFVP therapy or regimens containing Adriamycin. Further improvements in survival may be realized from the addition of hormonal and/or immune therapy to these active combinations as well as from the development of new drugs.